Background
==========

Periconceptional vitamin supplementation with folic acid substantially reduces risks of women having neural tube defect-affected pregnancies \[[@B1],[@B2]\] and has been implicated in reducing risks of several other congenital anomalies, including orofacial clefts and selected heart defects \[[@B3]-[@B11]\]. Mechanisms underlying these reduced risks have not been elucidated, although it has been speculated that supplementation with vitamins containing folic acid restores some normal developmental function that is genetically compromised in selected infants.

Investigating genetic variation that influences cellular absorption, transport, and metabolism of folate may offer insight into this unknown developmentally protective mechanism. Indeed, numerous investigations of genes that are specifically involved with folate metabolism have yielded at least one gene, 5, 10-methylenetetrahydrofolate reductase (*MTHFR*), that has been associated with a modest increased risk of neural tube defects (e.g., \[[@B12]-[@B17]\]), and possibly heart defects \[[@B18],[@B19]\]. Observed risks with the two principal *MTHFR*variants, however, do not appear to account for a large proportion of the etiologic fraction of any of these defects, under the assumption that *MTHFR*variants have a causal role \[[@B17]\]. Thus, further investigation of other folate-related genes is necessary to reveal clues about mechanisms underlying the potential embryonic protective effects of folic acid supplementation.

We hypothesized that genetic susceptibility of fetal metabolism or transport of folate puts fetuses at risk for selected congenital anomalies. Using population-based data, we investigated 118 single nucleotide polymorphisms (SNPs) in 14 genes in the complex folate pathway as risk factors for spina bifida and conotruncal heart defects.

Methods
=======

This population-based case-control study included infants with spina bifida or conotruncal heart defects diagnosed within 1 year after birth among infants and fetal deaths delivered to women residing in most California counties. Data were derived from the California Birth Defects Monitoring Program \[[@B20]\], a population-based active surveillance system for collecting information on infants and fetuses with congenital malformations. Diagnostic and demographic information was collected by program staff from multiple sources of medical records for all liveborn and stillborn fetuses (defined as \>20 weeks gestation). Overall ascertainment for major malformations has been estimated as 97% complete \[[@B21]\]. Eligible were live born infants only because the source of DNA was from newborn screening cards.

Included were 259 infants with spina bifida and a random sample of 359 nonmalformed control infants born during 1983--86 and 1994--95 in selected counties in California. Also included for study were 214 infants with conotruncal heart defects, specifically d-transposition of the great arteries and tetralogy of Fallot. The random sample of 1983--86 controls for conotruncal heart defects included 220 of the overall 359. Newborn bloodspots were obtained from the State of California and their use in this study was consistent with the consent procedures at the time of sample collection. The protocol for this study was reviewed and approved by the State of California Health and Welfare Agency Committee for the Protection of Human Subjects.

Genomic DNA was extracted from dried blood spots on filter paper using the Puregene DNA Extraction Kit (Gentra, Minneapolis, MN). Prior to genotyping, genomic DNA was amplified using a commercial multiple displacement amplification (MDA) kit, GenomePhi (GE Healthcare, Piscataway, NJ). The MDA method relies on isothermal amplification using the DNA polymerase of the bacteriophage phi29 and is a recently developed technique for high performance WGA. MDA has been demonstrated to be reliable for genotyping, with the most favorable call rates, best genomic coverage, and lowest amplification bias \[[@B22]\]. Studies indicate no discernable difference between WGA samples with GenomiPhi kit and the original DNA templates \[[@B23],[@B24]\]. The whole genome amplification (WGA) product was then quantified using RNase P method (AppliedBiosystems, Foster City, CA). 150 ng WGA product was then used for each SNPlex assay pool which contained about 48 SNPs.

Genotype analyses were performed using SNPlex assays (AppliedBiosystems, Foster City, CA). SNP markers were selected using the SNPBrowser™ program (version 3.0) provided by AppliedBiosystems Inc. This program allowed selection of SNP markers from the HapMap database. For each target gene, tagging SNPs were selected based on the pairwise r^2^\> = 0.8. SNPs with minor allele frequencies lower than 10% in Caucasians were excluded. All validated non-synonymous SNPs were included. Successful rates for SNPlex assays were \>96% for 75 SNPs, from 90% to 96% for 32 SNPs, from 70% to 90% for 7 SNPs. 15 SNPs suffered from more than 30% failure rates. In a subsequent effort to fill in the missing genotyping data and obtain higher call rate, we performed TaqMan SNP assays (Appliedbiosystems, Foster City, CA) for 22 of these SNPs on an ABI 7900 Genetic Analyzer.

All genotyping was performed blinded to subject\'s case or control status. Case and control infants were genotyped for 129 SNPs. Failure to obtain unambiguous genotype data on \>50% of the samples for 11 SNPs (*CBS*rs1801181 and rs12329790; *MTHFR*rs1537514 and rs7533315; *MTR*rs10925257, *NOS3*rs1800780 and hcv11631000; *RFC1*rs1051266, rs4819130, hcv16186310, and rs7278825) resulted in their elimination from further analyses. The remaining 118 SNPs are shown in Table [1](#T1){ref-type="table"}. The percentage of control study subjects (percentages were similar for cases) for whom genotype could be assigned is also shown in Table [1](#T1){ref-type="table"}.

###### 

Fourteen folate-related genes and 118 SNPs

  **Gene**   **Change**    **Chromosome**   **Base Position**   **SNP_ID**    **Type/Comment**                     **Percent Genotyped^1^**
  ---------- ------------- ---------------- ------------------- ------------- ------------------------------------ --------------------------
  *BHMT*     R (A/G)       5                78457715            rs3733890     exon, nonsynonymous R239Q            100
  *BHMT*     Y (C/T)       5                78471967            rs1915706     Intergenic/Unknown                   96.4
  *BHMT*     (G/C)         5                78567093            rs1316753     Tag, BHMT                            100
  *BHMT*     M (C/A)       5                78465350            rs617219      intergenic                           96.4
  *BHMT*     M (A/C)       5                78438303            rs645112      Intergenic/Unknown                   96.9
  *BHMT*     W (A/T)       5                78462964            rs585800      untranslated region                  94.2
  *BHMT*     S (C/G)       5                78559288            rs3829809     Tag, BHMT                            100
  *BHMT*     Y (C/T)       5                78452172            rs567754      intron                               95.8
  *BHMT2*    M (A/C)       5                78400443            rs642431      intergenic-BHMT2;intron-DMGDH        91.1
  *BHMT2*    R (A/G)       5                78405657            rs626105      intron                               96.1
  *BHMT2*    Y (C/T)       5                78409187            rs682985      exon, synonymous                     95.5
  *BHMT2*    M (A/C)       5                78387392            rs2253262     exon, synonymous                     96.4
  *BHMT2*    K(G/T)        5                78402082            rs670220      Validated                            96.7
  *BHMT2*    R (A/G)       5                78404048            rs592052      intron                               99.2
  *BHMT2*    R (A/G)       5                78419219            rs597560      intron                               98.3
  *CBS*      Y (T/C)       21               43360473            rs2851391     intron                               92.5
  *CBS*      R (A/G)       21               43359173            rs2298759     intron                               72.4
  *CBS*      Y (T/C)       21               43361102            rs234714      intron                               90
  *CBS*      S (C/G)       21               43346936            rs1051319     untranslated region                  91.9
  *CBS*      Y (T/C)       21               43376503            rs234784      Tag, CBS                             99.7
  *CBS*      N (A/C/G/T)   21               43346760            rs12613       untranslated region                  92.5
  *CBS*      S (C/G)       21               43377074            rs234785      Tag, CBS                             100
  *CBS*      R (A/G)       21               43360960            rs234713      intron                               91.1
  *CBS*      Y (C/T)       21               43376312            rs234783      Tag, CBS                             100
  *DHFR*     Y(C/T)        5                79986537            rs1650697     Validated nsSNP                      92.2
  *DHFR*     W(A/T)        5                79957572            rs12109877    Validated                            94.2
  *DHFR*     Y(C/T)        5                79987790            rs380691      Validated                            95.5
  *DHFR*     M(A/C)        5                79985331            rs1478834     Validated                            96.4
  *DHFR*     Y(C/T)        5                79966012            rs1643638     Validated                            92.8
  *DHFR*     M(A/C)        5                79961366            rs2618372     Validated                            96.9
  *DHFR*     R (A/G)       5                79980489            rs13161245    Validated                            96.1
  *DHFR*     Y(C/T)        5                79975899            rs1643650     Validated                            94.7
  *DHFR*     K(G/T)        5                79981467            rs836821      Validated                            97.5
  *FOLR1*    Y (C/T)       11               73373406            rs1540087     untranslated region                  95.8
  *FOLR1*    W (T/A)       11               73380857            rs11235462    Tag, FOLR1                           100
  *FOLR1*    R (A/G)       11               73372879            rs2071010     untranslated region                  91.9
  *FOLR2*    R (A/G)       11               73404256            rs2298444     intron                               92.2
  *FOLR2*    R (A/G)       11               73402049            rs514933      intron                               100
  *FOLR2*    W (A/T)       11               73401368            rs651646      untranslated region                  100
  *MTHFD1*   Y (C/T)       14               63984935            rs2236222     intron                               95.5
  *MTHFD1*   Y (C/T)       14               63978904            rs2236224     intron                               97.8
  *MTHFD1*   Y (C/T)       14               63952133            rs1950902     exon, nonsynonymous                  90.5
  *MTHFD1*   Y (C/T)       14               63978598            rs2236225     exon, nonsynonymous G1958A (R653Q)   100
  *MTHFD1*   (T/A)         14               63999040            hCV11462908   Tag, MTHFD1                          100
  *MTHFD1*   R (A/G)       14               63957808            hCV11660794   intron                               95.3
  *MTHFD1*   R (A/G)       14               63988165            rs11849530    intron                               95.8
  *MTHFD1*   R (A/G)       14               63990418            rs1256146     intron                               95
  *MTHFD1*   Y (C/T)       14               63985918            rs10137921    exon, nonsynonymous                  96.4
  *MTHFD1*   Y (C/T)       14               63980547            rs1256142     intron                               97.8
  *MTHFD2*   Y (T/C)       2                74304595            rs11126426    Intergenic, Tag                      100
  *MTHFD2*   (T/A)         2                74280806            rs702465      Intergenic, Tag                      96.7
  *MTHFD2*   R (A/G)       2                74313429            rs1667599     Intergenic, Tag                      100
  *MTHFD2*   R (A/G)       2                74340847            rs1667627     Validated                            96.1
  *MTHFD2*   W (A/T)       2                74333849            rs828858      Intergenic, Tag                      100
  *MTHFD2*   (C/G)         2                74281605            rs702466      Intergenic, Tag                      99.7
  *MTHFD2*   R (A/G)       2                74372559            rs7571842     Intergenic, Tag                      100
  *MTHFD2*   R (A/G)       2                74348376            rs828903      Validated                            94.4
  *MTHFR*    R (A/G)       1                11801310            rs3737964     Validated                            95.8
  *MTHFR*    R (A/G)       1                11823734            rs535107      Intergenic, Tag                      93.3
  *MTHFR*    K(G/T)        1                11798240            rs1931226     Validated                            96.9
  *MTHFR*    R(A/G)        1                11780518            rs4846048     Validated                            89.7
  *MTHFR*    Y (C/T)       1                11796598            rs7525338     Validated                            97.5
  *MTHFR*    R (A/G)       1                11785193            rs2274976     exon, nonsynonymous                  93
  *MTHFR*    Y (C/T)       1                11792217            rs4846052     intron                               96.9
  *MTHFR*    Y (C/T)       1                11790644            rs1801133     exon, nonsynonymous C677T            99.4
  *MTHFR*    R (A/G)       1                11775209            rs1889292     Intergenic, Tag                      100
  *MTHFR*    Y (C/T)       1                11797323            rs2066470     exon, synonymous                     95.3
  *MTHFR*    R (A/G)       1                11788723            rs4846051     exon, synonymous                     93
  *MTHFR*    R (A/G)       1                11786566            rs1476413     intron                               93.9
  *MTHFR*    M (A/C)       1                11788742            rs1801131     exon, nonsynonymous A1298C           99.7
  *MTR*      M (A/C)       1                233374717           rs2275565     Validated                            96.1
  *MTR*      Y (C/T)       1                233322616           rs1806505     intron                               97.5
  *MTR*      K(G/T)        1                233386474           rs3820571     Validated                            96.1
  *MTR*      Y (C/T)       1                233335898           rs3754255     Validated                            94.7
  *MTR*      S(C/G)        1                233381346           rs10802569    Validated                            96.1
  *MTR*      R (A/G)       1                233376992           rs1266164     intron                               96.1
  *MTR*      R (A/G)       1                233374541           rs1805087     exon, nonsynonymous A2756G           96.4
  *MTR*      W(A/T)        1                233385428           rs4659743     Validated                            98.3
  *MTR*      K(G/T)        1                233390667           rs6676866     Validated                            98.3
  *MTR*      S(C/G)        1                233315110           rs12060570    Validated                            98.6
  *MTR*      W(A/T)        1                233306545           rs955516      Validated                            99.2
  *MTR*      K (G/T)       1                233313831           rs4077829     intron                               96.7
  *MTR*      R (A/G)       1                233364202           rs1770449     intron                               94.4
  *MTR*      S (C/G)       1                233353709           rs3768139     intron                               95.5
  *MTR*      R (A/G)       1                233300165           rs4659724     intron                               97.2
  *MTR*      Y (C/T)       1                233327367           rs6668344     intron                               96.4
  *MTR*      R (A/G)       1                233367345           rs7367859     Validated                            93.9
  *MTR*      K (G/T)       1                233354605           rs3768142     Validated                            96.1
  *MTR*      Y (C/T)       1                233348403           rs10925252    Validated                            96.9
  *MTR*      R (A/G)       1                233380610           rs2229276     exon, synonymous                     95
  *MTR*      R (A/G)       1                233388346           rs1050993     untranslated region                  97.2
  *MTRR*     R (A/G)       5                7938959             rs162036      Validated nsSNP Lys/Arg              95.5
  *MTRR*     S (C/G)       5                7944506             rs16879334    exon, nonsynonymous Pro/Arg          90
  *MTRR*     R (G/A)       5                7950319             rs1802059     exon, synonymous                     94.7
  *MTRR*     R (G/A)       5                7942216             rs2287779     exon, synonymous                     97.2
  *MTRR*     R (A/G)       5                7927847             rs326120      intron                               87.7
  *MTRR*     Y (C/T)       5                7950191             rs10380       exon, nonsynonymous, His/Tyr         96.4
  *MTRR*     R (A/G)       5                7923973             rs1801394     exon, nonsynonymous                  96.7
  *MTRR*     Y (C/T)       5                7953712             rs9332        UTR                                  92.2
  *MTRR*     S (C/G)       5                7938907             rs10064631    exon, nonsynonymous                  95
  *MTRR*     W (A/T)       5                7931424             rs2303080     exon, nonsynonymous                  96.1
  *MTRR*     R (A/G)       5                7949511             rs3776455     intron                               95
  *MTRR*     R (A/G)       5                7931179             rs1532268     exon, nonsynonymous                  95
  *MTRR*     R (A/G)       5                7945310             rs162048      intron                               98.6
  *NOS3*     R (A/G)       7                150145737           rs891512      intron                               86.6
  *NOS3*     R (A/G)       7                150127591           rs1800779     untranslated region                  87.5
  *NOS3*     Y (C/T)       7                150148555           rs3918211     exon, synonymous                     96.9
  *RFC1*     K (G/T)       21               45761011            rs3788189     intron                               81.1
  *RFC1*     R (A/G)       21               45755537            rs12483377    Tag, RFC                             100
  *RFC1*     R (A/G)       21               45756112            rs2236484     Intron, Tag                          98.6
  *RFC1*     R (A/G)       21               45761386            rs3788190     Intron, Tag                          91.1
  *RFC1*     S (C/G)       21               45750430            rs10483080    intron                               99.7
  *RFC1*     Y (C/T)       21               45777720            rs2330183     intron                               91.4
  *TYMS*     Y (C/T)       18               652215              rs11540152    exon, nonsynonymous                  95.8
  *TYMS*     Y (C/T)       18               660414              rs2853532     intron                               96.4
  *TYMS*     R (A/G)       18               656371              rs2847149     intron                               97.2
  *TYMS*     Y (C/T)       18               652103              rs1001761     intron                               98.9
  *TYMS*     Y (C/T)       18               649236              rs502396      intron                               97.8

^1^Percent of 359 controls genotyped for each SNP.

Abbreviations: *BHMT*= betaine homocysteine methyltransferase; *BHMT2*betaine homocysteine methyltransferase-2; *CBS*= cystathione beta synthase; *DHFR*= dihydrofolate reductase; *FOLR1*folate receptor 1; *FOLR2*folate receptor 2; *MTHFD1*= methylenetetrahydrofolate dehydrogenase 1; *MTHFD2*= methylenetetrahydrofolate dehydrogenase 2; *MTHFR*= methylenetetrahydrofolate reductase; *MTR*= methionine synthase; *MTRR*= methionine synthase reductase; *NOS3*= nitric oxide synthase; *RFC1*= reduced folate carrier 1; *TYMS*= thymidylate synthase.

Genotypes among controls were analyzed to verify that their distributions fit Hardy-Weinberg expectations. Genotypes for each SNP were statistically consistent with Hardy-Weinberg expectations. Odds ratios and 95% confidence intervals (CI) were used to estimate risks. These measures were calculated using SAS software (version 9.1). Information on maternal race/ethnicity was obtained for case and control infants from California birth certificates. Logistic regression was used to compute risk estimates adjusted for maternal race/ethnicity (white Hispanic; white nonHispanic, and other). Analyses estimated defect risks (spina bifida or conotruncal heart defects) for each SNP assuming a recessive model, i.e., homozygous variant genotype compared to homozygous reference genotype and heterozygous variant genotype compared to homozygous reference genotype. In addition to single SNP-at-a-time analyses, we explored haplotype block analyses. Haplotype analyses were performed using Haploview version 3.32. Identified blocks were assessed with odds ratios.

Results
=======

Numbers of case and control infants stratified by race/ethnicity are shown in Table [2](#T2){ref-type="table"}. These data show the expected greater frequency of Hispanics in the spina bifida case group.

###### 

Racial/ethnic percentages of malformed cases and non-malformed controls, California 1983--86 and 1994--95.

  ----------------------------------------------------------------------------------------
                       **Spina Bifida**   **Conotruncal Heart**              
  -------------------- ------------------ ----------------------- ---------- -------------
                       Cases\             Controls\               Cases\     Controls\
                       n = 259\           n = 359\                n = 214\   n = 220^1^\
                       %^2^               %^2^                    %^2^       %^2^

                                                                             

  **Race/Ethnicity**                                                         

  White, Hispanic      50.6               31.5                    17.8       18.6

  White, nonHispanic   35.9               47.4                    53.3       61.8

  Other                12.0               20.6                    26.2       18.6
  ----------------------------------------------------------------------------------------

^1^The number of controls born in the period 1983--86 among the 359 selected for the overall study period 1983--86 and 1994--95. The 220 represent the birth years of cases with conotruncal heart defects.

^2^Percentages may not equal 100 owing to missing data or rounding.

We examined risks for each of the 118 SNPs and for each of the two birth defect outcome (Additional file [1](#S1){ref-type="supplementary-material"}). Few odds ratios (ORs) revealed sizable departures from 1.0. Given the large number of comparisons (n = 472) we expected more ORs to be substantially different from 1.0 by chance. With respect to spina bifida, we observed ORs with confidence intervals that did not include 1.0 for the following SNPs (heterozygous or homozygous) relative to the reference genotype: *BHMT*(rs3733890) OR = 1.8 (1.1--3.1), *CBS*(rs2851391) OR = 2.0 (1.2--3.1); *CBS*(rs234713) OR = 2.9 (1.3--6.7); *MTHFD1*(rs2236224) OR = 1.7 (1.1--2.7); *MTHFD1*(hcv11462908) OR = 0.2 (0--0.9); *MTHFD2*(rs702465) OR = 0.6 (0.4--0.9); *MTHFD2*(rs7571842) OR = 0.6 (0.4--0.9); *MTHFR*(rs1801133) OR = 2.0 (1.2--3.1); *MTRR*(rs162036) OR = 3.0 (1.5--5.9); *MTRR*(rs10380) OR = 3.4 (1.6--7.1); *MTRR*(rs1801394) OR = 0.7 (0.5--0.9); *MTRR*(rs9332) OR = 2.7 (1.3--5.3); *TYMS*(rs2847149) OR = 2.2 (1.4--3.5); *TYMS*(rs1001761) OR = 2.4 (1.5--3.8); and *TYMS*(rs502396) OR = 2.1 (1.3--3.3). Each gene involving multiple SNP associations was investigated for linkage disequilibrium. Modest to strong evidence for linkage disequilibrium was observed for SNPs in each gene, i.e., D\' ranged from 0.44 to 1.0 with all p values \< 10^-4^. With respect to conotruncal heart defects, we did not observe any OR with a confidence interval that did not include 1.0.

We did not observe evidence to indicate that risk patterns were confounded by race/ethnicity groupings, i.e., observed ORs were not substantially altered after adjusting for maternal race/ethnicity (not shown, available from authors upon request).

Haplotypes, reconstructed for each gene based on studied SNPs, were explored to assess risks for each case group. A total of 77 of the 118 studied SNPs formed 17 haplotype blocks. As shown in Table [3](#T3){ref-type="table"}, blocks for *TYMS*, *MTHFR*, *BHMT*, and *MTR*showed some evidence of nonrandom effects for spina bifida. For each of these haplotypes we observed decreased risk associated with the lower frequency haplotype relative to the most frequent haplotype. Similar to SNP analyses, haplotype analyses for conotruncal heart defects did not reveal evidence of nonrandom effects, with the exception of one haplotype block for *MTR*(Table [4](#T4){ref-type="table"}).

###### 

Haplotype associations with risks of spina bifida

  **Haplotype Block**     **Frequency**   **Odds Ratio (95% CI)**
  ----------------------- --------------- -------------------------
  ***TYMS***                              
  CGC                     0.500           REF
  TAT                     0.373           0.7 (0.6--0.9)
  TAC                     0.115           0.5 (0.3--0.7)
  ***MTRR***                              
  ATTAGCAACAC             0.264           REF
  ACTGGCAGTGT             0.213           1.4 (1.0--1.9)
  ACTAGCAACGC             0.201           0.8 (0.6--1.1)
  GCTAGCGGCGC             0.162           1.1 (0.7--1.5)
  ACAAAGAGCGC             0.055           1.1 (0.7--1.9)
  ACTAGCAGCGC             0.034           0.6 (0.3--1.3)
  ACTAAGAGCGC             0.027           1.2 (0.6--2.6)
  ACTGGCAGCGT             0.011           1.4 (0.5--4.1)
  ***MTHFR***\*                           
  GGG                     0.656           REF
  AGA                     0.163           0.9 (0.6--1.2)
  AGG                     0.121           0.9 (0.6--1.2)
  AAA                     0.057           0.6 (0.3--1.0)
  ***MTHFR***\*\*                         
  TCCCA                   0.368           REF
  CCCCA                   0.231           0.7 (0.5--0.9)
  CTCTG                   0.180           0.8 (0.6--1.1)
  CTTCG                   0.099           0.6 (0.4--0.9)
  CTCCG                   0.063           0.7 (0.5--1.2)
  CTCCA                   0.037           1.0 (0.5--1.8)
  ***CBS***                               
  CG                      0.889           REF
  TC                      0.055           1.2 (0.7--1.9)
  CC                      0.053           0.6 (0.3--1.0)
  ***RFC1***\*                            
  CG                      0.856           REF
  GG                      0.079           1.1 (0.7--1.7)
  GA                      0.063           1.0 (0.6--1.6)
  ***RFC1***\*\*                          
  TG                      0.486           REF
  GA                      0.463           0.9 (0.7--1.2)
  GG                      0.046           0.6 (0.3--1.0)
  ***MTHFD1***\*                          
  CT                      0.486           REF
  TC                      0.429           1.3 (1.0--1.6)
  CC                      0.080           0.9 (0.6--1.4)
  ***MTHFD1***\*\*                        
  GT                      0.825           REF
  AA                      0.167           0.9 (0.6--1.2)
  ***FOLR2***                             
  TA                      0.549           REF
  AG                      0.356           1.0 (0.8--1.3)
  AA                      0.093           1.0 (0.7--1.6)
  ***MTHFD2***\*                          
  TA                      0.589           REF
  CA                      0.321           1.1 (0.9--1.4)
  CG                      0.089           1.1 (0.7--1.6)
  ***MTHFD2***\*\*                        
  TC                      0.388           REF
  TT                      0.332           1.2 (0.9--1.5)
  AT                      0.276           1.0 (0.8--1.4)
  ***BHMT2***                             
  GGGTCA                  0.466           REF
  TAACTC                  0.219           1.0 (0.7--1.3)
  GAGCTC                  0.171           1.1 (0.8--1.6)
  GAGTCA                  0.091           1.0 (0.6--1.5)
  GGGTCC                  0.022           0.7 (0.3--1.7)
  ***BHMT***\*                            
  CAA                     0.339           REF
  TGA                     0.326           0.7 (0.5--0.9)
  CGT                     0.172           0.7 (0.5--1.0)
  CGA                     0.158           0.9 (0.6--1.2)
  ***BHMT***\*\*                          
  AC                      0.501           REF
  CT                      0.373           0.8 (0.7--1.1)
  AT                      0.120           0.9 (0.6--1.3)
  ***DHFR***                              
  CTTACCA                 0.402           REF
  CTTACCG                 0.390           0.9 (0.7--1.2)
  ACCGAAA                 0.201           0.9 (0.7--1.3)
  ***MTR***                               
  AATCTTTCCTAGAGGGCTTGG   0.373           REF
  GTGGCCCTGGGAAGAAGAGAT   0.262           1.0 (0.7--1.3)
  GTGGCCCTCTAGGTGACTTGG   0.190           0.9 (0.7--1.3)
  GTGGCCCTGGGGAGAAGAGAT   0.045           1.4 (0.8--2.5)
  GTGGCCTTCTAGATGACTTGT   0.040           0.6 (0.3--1.2)
  GTGGCCCTCGAAAGGAGTTGT   0.032           0.3 (0.1--0.6)

***TYMS***included rs1001761, rs2847149 and, rs2853532; ***MTRR***included rs326120, rs1532268, rs2303080, rs162036, rs2287779, rs16879334, rs162048, rs3776455, rs10380

rs1802059, and rs9332; ***MTHFR***\* included rs1889292, rs2274976, and rs1476413; ***MTHFR***\*\* included rs1801133, rs4846052, rs2066470, rs3737964, and rs535107; ***CBS***included rs12613 and rs 1051319; ***RFC1***\* included rs10483080 and rs12483377; ***RFC1***\*\* included rs3788189 and rs3788190; ***MTHFD1***\* included rs2236224 and rs1256142; ***MTHFD1***\*\* included rs1256146 and hcv11462908; ***FOLR2***included rs651646 and rs514933; ***MTHFD2***\* included rs11126426 and rs1667599; ***MTHFD2***\*\* included rs828858 and rs1667627; ***BHMT2***included rs670220, rs592052, rs626105, rs682985, rs597560, and rs645112; ***BHMT***\* included rs567754, rs3733890, and rs585800; ***BHMT***\*\* included rs617219 and rs1915706; ***DHFR***included rs2618372, rs1643638, rs1643650, rs13161245, rs836821, rs1478834, and rs380691; ***MTR***included rs4659724, rs955516, rs4077829, rs12060570, rs1806505, rs6668344, rs3754255, rs10925252, rs3768139, rs3768142, rs1770449, rs7367859, rs1805087, rs2275565, rs1266164, rs2229276, rs10802569, rs4659743, rs3820571, rs1050993, and rs6676866.

###### 

Haplotype association with risks of conotruncal heart defects

  **Haplotype**           **Frequency**   **Odds Ratios (95% CI)**
  ----------------------- --------------- --------------------------
  **Block 19 (*MTR*)**                    
  AATCTTTCCTAGAGGGCTTGG   0.354           REF
  GTGGCCCTGGGAAGAAGAGAT   0.272           1.1 (0.7--1.5)
  GTGGCCCTCTAGGTGACTTGG   0.189           1.2 (0.8--1.8)
  GTGGCCTTCTAGATGACTTGT   0.048           1.5 (0.8--3.0)
  GTGGCCCTCGAAAGGAGTTGT   0.035           1.0 (0.5--2.1)
  GTGGCCCTGGGGAGAAGAGAT   0.021           0.9 (0.3--2.2)
  GATCTTTCCTAGAGGGCTTGG   0.013           10.7 (1.4--84.8)

Block 19 included rs4659724, rs955516, rs4077829, rs12060570, rs1806505, rs6668344, rs3754255, rs10925252, rs3768139, rs3768142, rs1770449, rs7367859, rs1805087, rs2275565, rs1266164, rs2229276, rs10802569, rs4659743, rs3820571, rs1050993, and

rs6676866.

Haplotype analyses were stratified by race/ethnic background (Hispanic white and nonHispanic white). We observed evidence of a nonrandom haplotype association with *TYMS*for spina bifida and conotruncal heart defects among nonHispanic whites. Lack of evidence for other haplotypes that were observed overall was likely the result of smaller sample sizes from stratification.

Discussion
==========

In this California population we found only modest evidence that polymorphisms in 14 folate-related genes contributed to risk of spina bifida. SNPs contributing risks were in *BHMT*, *CBS*, *MTHFD1*, *MTHFD2*, *MTHFR*, *MTRR*, and *TYMS*. Haplotype association analyses further identified *TYMS*and *MTHFR*as potential contributors to spina bifida risk. In general, however, most of these folate-related genes showed little evidence for a gene-only effect on risk of spina bifida, and even less, on risks of conotruncal heart defects.

The 14 genes studied here have been implicated in the complex metabolic cycle involving folate (e.g., \[[@B25]-[@B27]\]). To our knowledge, this study contained the largest number of SNPs in folate-related genes interrogated as risk factors for human spina bifida or conotruncal heart defects. Previous studies have included some of the SNPs examined here. For example, Boyles and colleagues \[[@B28]\] studied 28 SNPs in 11 folate-related genes and found that only *BHMT*(rs3733890) was associated with increased spina bifida risk. This *BHMT*association is consistent with our findings that showed an odds ratio of 1.8 (1.1--3.1).

Many studies have explored *MTHFR*677 (rs1801133) polymorphism. A range of risks, including no-effect, has been reported for this SNP relative to spina bifida. Botto and Yang \[[@B15]\] in a meta-analysis demonstrated a pooled odds ratio of 1.8 for spina bifida among infants homozygous for 677T. A few studies have also explored this 677 SNP in *MTHFR*as a risk factor for selected congenital heart defects, with most investigations finding no or little association \[[@B18],[@B19],[@B29]-[@B31]\]. We did observe a 2-fold increased risk of spina bifida associated with this SNP for homozygous infants. Further, haplotype analyses showed some association for the *MTHFR*gene as well.

Methionine synthase (MTR) is a vitamin B~12~dependent enzyme that is essential for the remethylation of homocysteine to methionine. The enzyme is required by cells for the essential accumulation of folate \[[@B32]\]. One particular SNP (A2756G; rs1805087) has been considerably investigated, with increased risks of NTDs reported in some studies \[[@B33]-[@B35]\], but not in others \[[@B36],[@B37]\]. We did not find an increased risk for spina bifida or conotruncal heart defects associated with this SNP or any other SNP of *MTR*.

Cystathione beta synthase (CBS) is critical to the degradation of homocysteine to cysteine. Regulation of this pyridoxal phosphate-dependent enzyme catalyzes the hydroxyl group of serine with the thiolate of homocysteine \[[@B38]\]. The polymorphism in the *CBS*gene that has received the most study is a 68 bp insertion (844ins68), with predominantly no associations observed for NTDs \[[@B27]\]. This polymorphism was not investigated in the current study. We did observe, however, two *CBS*SNPs (rs2851391 and rs234713) that showed increased risks for spina bifida. Boyles et al \[[@B28]\], albeit using a different study design than ours, observed that these two SNPs were not differentially transmitted from parents of infants with spina bifida.

*MTRR*gene polymorphisms (particularly rs1801394) have been investigated as a risk factor for both spina bifida and congenital heart defects. Polymorphisms in *MTRR*could alter homocysteine levels because methionine synthase reductase participates in maintaining the vitamin B~12~-dependent conversion of homocysteine to methionine \[[@B32]\]. The most frequently studied *MTRR*polymorphism has been the 66A\>G (rs1801394). This polymorphism in infants was associated with a 2.6-fold increased risk of spina bifida in an earlier study by us \[[@B33]\], it was associated with increased risk for spina bifida in another study only when vitamin B~12~levels were low \[[@B39]\], or in combination with MTHFR CC genotype \[[@B35]\]. The polymorphism in mothers of infants with neural tube defects has been associated with increased risk in one study \[[@B40]\], but not in another study \[[@B41]\]. Recent work from the Netherlands has shown a lack of association between this polymorphism and risk for conotruncal heart defects \[[@B42]\] as well as no increased risks for a broader phenotypic group of heart defects \[[@B43]\]. In this study, the 66A\>G polymorphism was not associated with increased risks for either spina bifida or conotruncal heart defects. We did observe, however, approximately 3-fold elevated risks for spina bifida associated with three other *MTRR*SNPs (rs162036, rs10380, and rs9332). The significance of these observations will have to be explored in future studies.

With respect to *MTHFD1*and *MTHFD2*, two studies have demonstrated an association with one polymorphism (rs 2236225) in *MTHFD1*and NTD risk. One study showed a 1.5-fold increase in risk of an NTD-affected pregnancy in Irish women who were homozygous AA \[[@B44]\], a finding that confirmed an earlier increased risk that was identified in Irish women. Another study showed a similar risk for Italian women as well as a 1.9-fold risk for infants with the AA genotype to have spina bifida \[[@B45]\]. For this particular SNP, we observed a similar magnitude of risk (OR = 1.6) for infants with the homozygous genotype, but the estimate was relatively imprecise. We did observe a modestly elevated spina bifida risk for individuals who were homozygous for another *MTHFD1*SNP (rs2236224) and modestly lowered risks for three others (hcv11462908, rs702465, and rs7571842). These observations will need to be replicated in future studies.

Polymorphisms in the *DHFR*gene have not been well-studied for their role in risks of birth defects. Three studies have investigated a 19-bp deletion with mixed results \[[@B46]-[@B48]\]. That particular polymorphism was not interrogated in the current study.

Our analyses did not show associations with SNPs in *RFC1*. Previous investigations of this gene have focused on a particular SNP, rs1051266, and have found mixed results \[[@B37],[@B41],[@B49]-[@B53]\]. This particular SNP was not analyzed here as a result of too many samples failing to be genotyped for this SNP using the SNPlex platform.

Recent studies have focused on the importance of *TYMS*in the folate metabolic pathway, including associations between *TYMS*polymorphisms and folate levels \[[@B54]-[@B56]\]. This folate-dependent enzyme catalyzes the reductive methylation of deoxyuridylate (dUMP) to thymidylate (dTMP), thereby playing a central role in DNA synthesis and repair by serving as the primary intracellular source of dTMP \[[@B54],[@B57]-[@B59]\]. We previously \[[@B56]\] observed a 4-fold increased risk of spina bifida in nonHispanic white infants who had a polymorphism for a 28 bp insertion in the promoter region. This observation, however, was not replicated in a population from the northern UK \[[@B55]\]. This particular polymorphism was not interrogated in the current study. Three of the five *TYMS*SNPs (rs284179, rs1001761, and rs502396) investigated here showed elevated risks for spina bifida for both heterozygote or homozygote individuals. This finding and the corresponding haplotype finding (Table [3](#T3){ref-type="table"}) will be important to explore in future studies.

The strengths of this study were: 1) it investigated the potential effects of a large number of folate pathway SNPs, as well as investigated haplotype associations; 2) it had population-based ascertainment of two case phenotypes and controls; and 3) it included cases and controls born before the US food supply was fortified with folic acid, thus we would expect a sizable proportion of cases to have been folate-responsive.

Conversely, our study was limited in its effect estimation owing to small sample sizes for some comparisons. For example, our study had 80% power to detect risks of 2.5 or more associated with genotypes that were observed in at least 4% of controls. Another potential limitation is the lack of information on maternal folate status. Our working hypothesis is that transient elevation in maternal serum folate from supplementation or dietary intake could prevent birth defects by overcoming metabolic inefficiencies or transport-related issues. Absence of information on low folate status would make it more difficult to find putative genotypes. It is also possible that the protective effect of folic acid relates to correction of a maternal metabolic defect, rather than the fetus. Our study was limited to infant genotype information. Thus, we were unable to investigate the potential effects of maternal genotype. As with any study that seeks to explore associations with a large number of genotypes, findings are subject to chance owing to multiple comparisons. As noted above, we conducted 472 analytic comparisons and thus expected more \"statistically significant\" findings to arise by chance alone. Further, our findings may have been influenced by uncontrolled confounding by population stratification undetectable in analyses stratified or adjusted by race/ethnicity \[[@B60],[@B61]\]. Lastly, the selected SNPs represent only a fraction of the potential variation of the studied genes. Thus, full gene coverage was not achieved even though a large number of SNPs was studied.

Conclusion
==========

Despite compelling evidence that folate intake by women in early pregnancy substantially reduces risks of selected birth defects, the underlying mechanisms have not been elucidated. Our study attempted to determine genetic mechanisms responsible for folic acid\'s preventive effects. Our observations do not implicate a particular folate transport or metabolism gene to be strongly associated with risks for spina bifida or conotruncal defects. Although we explored a sizable number of polymorphic areas in these genes, we clearly did not capture all the genetic variation. Thus, these genes may continue to be candidates for further inquiry. Alternatively, the preventive role of folate may be via other biological mechanisms such as methylation of nonfolate-related genes that participate in the closure of the neural tube or the development of the heart.
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